Ziling Liu
YOU?
Author Swipe
View article: SCORP: Scene-Consistent Object Refinement via Proxy Generation and Tuning
SCORP: Scene-Consistent Object Refinement via Proxy Generation and Tuning Open
Viewpoint missing of objects is common in scene reconstruction, as camera paths typically prioritize capturing the overall scene structure rather than individual objects. This makes it highly challenging to achieve high-fidelity object-lev…
View article: Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer
Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer Open
Purpose Combination strategies involving immune checkpoint inhibitors (ICIs) have been a prominent focus of research in the treatment of non-small cell lung cancer (NSCLC). Our prior findings demonstrated that the combination of autologous…
View article: Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study Open
Background The data for dacomitinib, a second-generation EGFR-TKI, treating patients with advanced non-small cell lung cancer (NSCLC) and brain metastasis was lacking. This study aimed to explore the efficacy and safety of dacomitinib in t…
View article: Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer
Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer Open
Receiving ≥6 cycles of induction chemotherapy significantly prolonged the median PFS and median OS of patients, highlighting its crucial factor influencing the efficacy of first-line atezolizumab combined with chemotherapy in patients with…
View article: Case report: Pancreatic metastasis from small-cell lung cancer appears as primary G2 pancreatic neuroendocrine tumor on combined contrast PET imaging with three probes
Case report: Pancreatic metastasis from small-cell lung cancer appears as primary G2 pancreatic neuroendocrine tumor on combined contrast PET imaging with three probes Open
Pancreatic metastasis is a rare malignant tumor; when it comes to multiple cancers, it may be a challenge to identify the primary lesion of new pancreatic metastases. With the continuous advancement of imaging technology, the PET/computed …
View article: Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial Open
Zai Lab (Shanghai) Co., Ltd; National Major Scientific and Technological Special Project for "Significant New Drugs Development" in 2018, China [grant number 2018ZX09736019].
View article: Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report
Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report Open
Chromophobe renal cell carcinoma (ChRCC) is a rare pathological type of renal cell carcinoma (RCC). Related systematic studies involving large numbers of patients are lacking, and more importantly, there is currently no international conse…
View article: A phase Ib study evaluating the safety and efficacy of <scp>IBI310</scp> plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after <scp>anti‐PD</scp>‐1/<scp>L1</scp> therapy
A phase Ib study evaluating the safety and efficacy of <span>IBI310</span> plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after <span>anti‐PD</span>‐1/<span>L1</span> therapy Open
Background The development of immune checkpoint inhibitors has made a significant breakthrough in the treatment of non‐small‐cell lung cancer (NSCLC). However, there remains a huge unmet clinical need for patients with acquired resistance …
View article: Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials Open
PURPOSE To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti–human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients with HER2-positive locall…
View article: Immunotherapy: a promising approach for glioma treatment
Immunotherapy: a promising approach for glioma treatment Open
Gliomas are the most prevalent primary malignant brain tumors worldwide, with glioblastoma (GBM) being the most common and aggressive type. Despite two decades of relentless pursuit in exploring novel therapeutic approaches for GBM, there …
View article: Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19
Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19 Open
Background The coronavirus disease 2019 (COVID-19) pandemic has resulted in infections among patients with cancer. Our study aimed to investigate the potential adverse impact of anti-cancer treatments within 2 weeks of COVID-19 infection o…
View article: Bibliometric study of immunotherapy for hepatocellular carcinoma
Bibliometric study of immunotherapy for hepatocellular carcinoma Open
Background Hepatocellular carcinoma (HCC), recognized as a significant global health concern, ranks as the sixth most prevalent form of cancer and is the third leading cause of cancer-associated mortality. Over half of HCC patients are dia…
View article: Endoscopic reintervention after unilateral metal stent deployment for MHBO using SIS method
Endoscopic reintervention after unilateral metal stent deployment for MHBO using SIS method Open
Endoscopic biliary drainage is the main treatment for unresectable malignant hilar biliary obstruction (MHBO). Recurrent biliary obstruction (RBO) often occurs after unilateral metal stent deployment. Endoscopic reintervention can be compl…
View article: Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer Open
Importance The efficacy of niraparib maintenance therapy with an individualized starting dose (ISD) warrants further investigation in a broad population with newly diagnosed advanced ovarian cancer (aOC), including patients without postope…
View article: Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study Open
Background Concurrent programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors with sequential chemoradiotherapy (SCRT) have been reported in only a limited number of studies involving patients with unresectable stage III …
View article: Supplemental Table 1-3 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Supplemental Table 1-3 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 Open
Supplemental Table 1. Grade 3 and above treatment-related adverse events in the study; Supplemental Table 2. Biomarker and subgroup analysis for correlation with clinical efficacy in all 151 patients; Supplemental Table 3. PD-L1 JS311 IHC …
View article: Supplemental Figure 3 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Supplemental Figure 3 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 Open
The mutational signature characterized by exposure to aristolochic acid.
View article: Data from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Data from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 Open
Purpose:Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety…
View article: Supplemental Figure 1 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Supplemental Figure 1 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 Open
Cross correlation study among different PD-L1 IHC staining antibodies.
View article: Data from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Data from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 Open
Purpose:Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safety…
View article: Placental chorioangioma and pregnancy outcome: A ten-year retrospective study in a tertiary referral centre
Placental chorioangioma and pregnancy outcome: A ten-year retrospective study in a tertiary referral centre Open
Background Placental chorioangioma is a rare disorder in pregnancy. We retrospectively reviewed the perinatal complications and long-term outcomes in pregnancies with placental chorioangioma and evaluated the factors affecting disease prog…
View article: Bibliometric and visualization analysis of immunogenic cell death from 2012 to 2022 (Preprint)
Bibliometric and visualization analysis of immunogenic cell death from 2012 to 2022 (Preprint) Open
BACKGROUND In recent years, immunogenic cell death (ICD) has been intensively studied. ICD is a form of regulated cell death (RCD) that is sufficient to trigger an adaptive immunological response specific for antigens produced on dying ce…
View article: Bibliometric and visual analyses of trends in the field of T cell exhaustion research: Findings from 2000 to 2022
Bibliometric and visual analyses of trends in the field of T cell exhaustion research: Findings from 2000 to 2022 Open
Background T cell exhaustion refers to a state wherein T cells become less functional as a result of their prolonged exposure to cognate antigens. A wealth of T cell exhaustion-focused research has been conducted in recent decades, transfo…
View article: Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy Open
This pilot study (NCT03958097; https://www.clinicaltrials.gov/ct2/show/NCT03958097 ) was aimed to evaluate the efficacy and safety of PD-1 antibody combined autologous NK cells in the treatment of patients with stage IIIB/IIIC or IV non-sm…
View article: Thrombosis and lymphocyte subsets of COVID-19 omicron BA.2 variant patients with cancer
Thrombosis and lymphocyte subsets of COVID-19 omicron BA.2 variant patients with cancer Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an ongoing global pandemic of COVID-19. It has been found that COVID-19 has an influence on the changes of blood coagulation parameters and the high incidence of thrombosi…
View article: Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer Open
Clinicaltrials.gov Identifier: NCT04348032.
View article: Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin [Corrigendum]
Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin [Corrigendum] Open
[This corrects the article DOI: 10.2147/IJN.S280187.].
View article: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 Open
Purpose: Immunotherapy offers a second-line option for patients with metastatic urothelial carcinoma (mUC) who failed standard therapy, but the biomarkers for predicting response remain to be explored. This study aims to evaluate the safet…
View article: Primary uterine broad ligament ependymoma with <scp><i>CHEK2</i></scp><i>p.<scp>H371Y</scp></i> germline mutation: A <scp>CARE</scp>‐compliant case report uterine broad ligament ependymoma
Primary uterine broad ligament ependymoma with <span><i>CHEK2</i></span><i>p.<span>H371Y</span></i> germline mutation: A <span>CARE</span>‐compliant case report uterine broad ligament ependymoma Open
Ependymomas arise from ependymal cells lining the ventricles and central canal of the spinal cord and can occur throughout the whole neuraxis. The lesion rarely occurs in extracranial or extraspinal regions, particularly in the uterine bro…
View article: TP53 in Myelodysplastic Syndromes
TP53 in Myelodysplastic Syndromes Open
Myelodysplastic syndromes (MDSs) are heterogeneous for their morphology, clinical characteristics, survival of patients, and evolution to acute myeloid leukemia. Different prognostic scoring systems including the International Prognostic S…